Evidence map›Paper›PMID 32942339›Full record

ArticleJournal of cellular and molecular medicine2020

Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility.

Hong-Jin Zhao, Xiao-Mei Yang, Ai-Hong Wang, Yan Li

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hong-Jin ZhaoDepartment of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.ORCID 0000-0001-5296-2293
Xiao-Mei YangDepartment of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, China.ORCID 0000-0002-4081-4207
Ai-Hong WangDepartment of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
Yan LiSchool of Medicine, Cheeloo College of Medicine, Shandong University, Ji'nan, China.ORCID 0000-0003-1813-8115

Funding

China Scholarship Council 201706225023Fundamental Research Funds of Shandong University 21520079614029Shandong Provincial Natural Science Foundation of China ZR2015PH036
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnimalsAntihypertensive AgentsComorbidityCOVID-19FemaleHumansHypertensionPremenopauseACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive Agents

Identifiers

PMID32942339
PMCPMC7537110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.